Therapeutic Response

pMMR status confers therapeutic sensitivity to Carboplatin in combination with Durvalumab, Olaparib, and Paclitaxel in patients with Endometrial Carcinoma.

Statements

Source and description

Imfinzi (durvalumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).